Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ruxolitinib in Patients With Breast Cancer

This study has been terminated.
(Not enough responses to continue treatment.)
Information provided by (Responsible Party):
Nancy Lin, MD, Dana-Farber Cancer Institute Identifier:
First received: March 20, 2012
Last updated: November 25, 2015
Last verified: November 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2014
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)